Earnings ·
Autolus reports Q3 net product revenue of $41.2M, raises full-year guidance to at least $150M
AUTLAutolus Therapeutics plc
Autolus Therapeutics reported third-quarter 2026 net product revenue of $41.2 million, a 95% increase from the prior year period, driven by growing demand for AUCATZYL in existing and new treatment centers. The company raised its full-year 2026 AUCATZYL net product revenue guidance to at or exceeding the upper end of $150 million. Gross margin improved to 57% due to manufacturing efficiency initiatives, while R&D expenses rose to $30.9 million and SG&A decreased slightly to $35.9 million. The company reported a net loss of $55.1 million for the quarter compared to $79.1 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $248.4 million at September 30, 2026. Autolus Therapeutics is a commercial-stage biopharmaceutical company developing, manufacturing, and delivering next-generation T cell therapies for cancer and autoimmune diseases.